Turbo Energy, S.A. American Depositary Shares (TURB)

VALENCIA, Spain, June 26, 2024 (GLOBE NEWSWIRE) -- Turbo Energy, S.A. (NASDAQ:TURB) (“Turbo Energy” or the “Company”), a leader in the field of photovoltaic energy storage, today announced that the following proposals were approved at its 2024 Annual General Meeting of Shareholders held on June 25, 2024 in Valencia, Spain:

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion. RayzeBio shares gained 100% to $61.38 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers ARB IOT Group Limited (NASDAQ: ARBB) shares rose 270% to $3.4850 after gaining around 18% on Friday. IMAC Holdings, Inc. (NASDAQ: BACK) shares jumped 108% to $5.05 after jumping 53% on Friday. Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) jumped 75% to $2.0988 after the company announced 95% accuracy results for HYLA blood sensor. Gracell Biotechnologies Inc. (NASDAQ: GRCL) shares gained 60.3% to $9.92 after AstraZeneca announced plans to buy Gracell Biotechnologies for up to $1.2 billion. Science 37 Holdings, Inc. (NASDAQ: SNCE) jumped 52% to $6.62. Science 37 Holdings got notification from Nasdaq indicating the company regained compliance with minimum closing bid price requirement for continued listing. Volcon, Inc. (NASDAQ: VLCN) rose 49.8% to $0.1483 after jumping around 24% on Friday. Sight Sciences, Inc. (NASDAQ: SGHT) gained 48.9% to $5.42. AERWINS Technologies Inc.(NASDAQ: AWIN) gained 36.4% to $0.1637 after the company entered into a letter of intent to form an entity with Helicopter Technology. The company will own 70% and Helicopter Technology will own 30%. SCWorx Corp. (NASDAQ: WORX) rose 32% to $2.3349 after the company announced that it signed a definitive agreement and plan of merger with American Environmental Partners. 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) gained 30% to $1.1750 after the company announced IRB approval of its Phase IIA clinical study ...